Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study
Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study
复制标题
DOI：
10.1002/hep.30050
复制
发表时间：
2018-11-01
期刊：
影响因子：
13.5
通讯作者：
Wat, Cynthia
中科院分区：
文献类型：
--
作者：
Wirth, Stefan;Zhang, Hongfei;Wat, Cynthia
儿童慢性B型肝炎（CH B）代表了一个未满足的医疗需求领域，这归因于与成人CH B患者相比，CH B后遗症的终生风险增加和治疗选择有限。PEG-B-ACTIVE（NCT 01519960）III期研究评价了聚乙二醇干扰素（PegIFN）α-2a治疗3至
Children with chronic hepatitis B (CHB) represent an area of unmet medical need, attributed to increased lifetime risk of CHB sequelae and limited therapeutic options compared with adult CHB patients. The PEG-B-ACTIVE (NCT01519960) phase III study evaluated peginterferon (PegIFN) alfa-2a treatment in children aged 3 to